Tiny Gem

Personalized Vaccines are Giving More Patients Hope After Brain Cancer Diagnosis

Personalized vaccines are giving more brain cancer patients reason to hope, and at UCLA, one tested in clinical trials has helped about two dozen people with glioblastoma live far longer than expected. Doctors are now working to extend that benefit to the thousands of brain tumor patients who need it. 

Glioblastoma ranks among the deadliest brain tumors, nearly always returning even after surgery, radiation and chemotherapy, and barely any patients live beyond five years. The tumor also hides from the body’s defenses because it holds few T cells, the immune cells that attack cancer, which leaves immunotherapy with little to work with. 

Called DCVax-L, the vaccine takes a different route by training dendritic cells, which act as scouts for the immune system, to recognize the tumor. Doctors combine a tumor sample from surgery with dendritic cells grown from the patient’s blood, then expose the cells to tumor proteins in the lab. Once re-injected, they help trigger an immune attack. Because each vaccine is built from one person’s tumor, no two are identical. 

Linda Liau, a neurosurgeon, and Robert Prins, a tumor immunologist, lead the trials, and their team at the UCLA Health Jonsson Comprehensive Cancer Center has worked on this problem for over twenty years. A notable group of patients has lived past the five-year mark. 

One patient who has gone well beyond that mark is Jamil Newirth, who is now 46 and practices law in Maui. In 2012, aged 32 and newly out of law school, he was told he had under a year and a half to live, but he joined Liau’s trial and gives the vaccine partial credit for his survival. 

Beyond the vaccine alone, Liau’s team is testing combinations with other drugs. Checkpoint inhibitors, which free immune cells from signals that hold them back, have reshaped care across multiple cancer types, yet they have done little against glioblastoma alone, probably because too few T cells are present. The vaccine could fill that gap by drawing T cells into the tumor first, where the inhibitor then keeps them working. Researchers are also studying treatment timing, and Liau doubts any single drug will work for every patient, since glioblastoma varies so widely. 

A second UCLA trial applies the idea to H3 G34-mutant diffuse hemispheric glioma, a rare cancer that mostly affects people from adolescence into young adulthood. Neurosurgeon Anthony Wang leads the study with Liau and Prins. Participants receive a vaccine built from their own dendritic cells, which targets flawed proteins that result from altered genetic processing inside tumor cells. This first-in-human trial will assess safety and whether the immune response endures. 

Concurrently, many other firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are investing in developing the next generation of medicines indicated for brain cancers. As these efforts progress, a lot more patients could get treatment alternatives that deliver lasting results. 

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Alex Pearon

Share
Published by
Alex Pearon
Tags CNSP

Recent Posts

Study Discovers Possible Reason for Immunotherapy Not Working in Some Patients

Researchers at the University of Connecticut may have found one of the reasons why immunotherapy…

5 days ago

AI Data Centers Could Hamstring the UK’s Climate Goals

BBC research says the massive AI data center construction occurring across the UK threatens to…

1 week ago

Global Coal Demand is Outstripping Supply, Bank of America Says

A recent report from Bank of America (BofA) has revealed that global demand for coal…

2 weeks ago

Study Finds That Cerebrospinal Fluid Contains DNA of Complex Brain Tumors

A recent study undertaken by Mayo Clinic suggests that physicians can gain crucial brain tumor-related…

2 weeks ago

New Immunotherapy Prolongs Survival of Lung Cancer Patients

A combination of two immunotherapy drugs has significantly extended survival in patients with one of…

3 weeks ago

Report Says New Coal Projects Outnumber Cancelled Ones 

Figures published in German environmental group Urgewald’s annual coal industry database have revealed that new…

3 weeks ago